Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 18/20 | 0.55 |
| ▸ | MMP2 | P08253 | 15/20 | 0.55 |
| ▸ | MMP3 | P08254 | 13/20 | 0.55 |
| ▸ | MMP9 | P14780 | 13/20 | 0.55 |
| ▸ | MMP8 | P22894 | 9/20 | 0.52 |
| ▸ | MMP14 | P50281 | 3/20 | 0.52 |
| ▸ | MMP12 | P39900 | 1/20 | 0.52 |
| ▸ | MMP7 | P09237 | 10/20 | 0.52 |
| ▸ | MMP13 | P45452 | 10/20 | 0.52 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6336327 | 0.88 | MMP1 (0.56) | MMP1MMP2MMP3MMP9MMP8 | |
| SCHEMBL6863639 | 0.79 | MMP1 (0.56) | MMP1MMP2MMP3MMP9MMP8 | |
| SCHEMBL6267902 | 0.78 | MMP1 (0.67) | MMP1MMP2MMP3MMP9MMP8 | |
| SCHEMBL6339420 | 0.78 | MMP1 (0.68) | MMP1MMP2MMP3MMP9MMP8 | |
| SCHEMBL6344484 | 0.77 | MMP1 (0.83) | MMP1MMP2MMP3MMP9MMP8 | |
| SCHEMBL7758653 | 0.77 | MMP1 (0.83) | MMP1MMP2MMP3MMP9MMP8 | |
| SCHEMBL6271303 | 0.74 | MMP1 (0.55) | MMP1MMP2MMP3MMP9MMP8 | |
| SCHEMBL7763224 | 0.74 | MMP1 (0.55) | MMP1MMP2MMP3MMP9MMP8 | |
| SCHEMBL7537969 | 0.72 | MMP1 (0.71) | MMP1MMP2MMP3MMP9MMP8 | |
| SCHEMBL7537963 | 0.72 | MMP1 (0.71) | MMP1MMP2MMP3MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1596846-A2 | INHIBITORS OF HEPATITIS C VIRUS, COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2005-11-23 | — | — | EP | claimed |
| US-20040229817-A1 | Inhibitors of Hepatitis C virus, compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2004-11-18 | — | — | US | claimed |
| WO-2004073599-A2 | INHIBITORS OF HEPATITIS C VIRUS, COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2004-09-02 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-1596846-A2 | INHIBITORS OF HEPATITIS C VIRUS, COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20040235952-A1 | Inhibitors of severe acute respiratory syndrome (SARS) 3C-like proteinase | AGOURON PHARMACEUTICALS, INC. | 2004-11-25 | — | — | US | disclosed |
| US-20040229817-A1 | Inhibitors of Hepatitis C virus, compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2004-11-18 | — | — | US | disclosed |
| WO-2004093860-A1 | INHIBITORS OF SARS RELATED CORONAVIRUS PROTEINASE | PFIZER INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004073599-A2 | INHIBITORS OF HEPATITIS C VIRUS, COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229817-A1 | Inhibitors of Hepatitis C virus, compositions and treatments using the same | TIMP3, MMP2, MMP7 | MMP1 10/4885MMP2 2/4885MMP3 5/4885 |
| US-20040235952-A1 | Inhibitors of severe acute respiratory syndrome (SARS) 3C-like proteinase | ACE, ACE2, PRSS3 | MMP1 433/4885MMP2 87/4885MMP3 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.